{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:41:35Z","timestamp":1790959295832,"version":"4.1.0"},"reference-count":26,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2013,10,15]],"date-time":"2013-10-15T00:00:00Z","timestamp":1381795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:p>Objective: Review pharmacology, pharmacokinetics, efficacy, and safety of ziv-aflibercept in combination with FOLFIRI for treatment of metastatic colorectal cancer (mCRC) resistant to or progressed following oxaliplatin-containing regimens. Data Sources: Articles indexed in PubMed (1948-August 2013), TOXLINE (2001-August 2013), and Google Scholar as well as meeting abstracts were identified using the search terms ziv-aflibercept and colorectal cancer. Study Selection and Data Extraction: Available English-language articles Data Synthesis: Ziv-aflibercept, a selective vascular endothelial growth factor antagonist, was evaluated as monotherapy for treatment of mCRC in a phase 2 study and added to FOLFIRI in a phase 3 trial. Patient response to ziv-aflibercept as monotherapy did not reach statistical significance. Results suggest that response to ziv-aflibercept treatment is not influenced by prior bevacizumab therapy. A phase 3 trial compared the safety and efficacy of ziv-aflibercept plus FOLFIRI with placebo plus FOLFIRI in patients with mCRC who experienced disease progression on an oxaliplatin-containing regimen. Patients in the ziv-aflibercept arm had a median overall survival of 13.5 months, versus 12.06 months for those receiving placebo (hazard ratio [HR] = 0.817, 95% CI = 0.713 to 0.937). Progression-free survival for patients receiving ziv-aflibercept was higher compared with placebo (HR = 0.758; 95% CI = 0.661 to 0.869). The most common adverse effects observed were anemia, diarrhea, and neutropenia. Conclusions: Ziv-aflibercept is a safe and effective option in combination with FOLFIRI for the treatment of mCRC in patients who progress on oxaliplatin-containing therapy. Superiority over other antiangiogenic treatment has not been established.<\/jats:p>","DOI":"10.1177\/1060028013506562","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T15:04:57Z","timestamp":1390316697000},"page":"93-98","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["Ziv-aflibercept (Zaltrap) for the Treatment of Metastatic Colorectal Cancer"],"prefix":"10.1177","volume":"48","author":[{"given":"Scott L.","family":"Perkins","sequence":"first","affiliation":[{"name":"Wingate University School of Pharmacy, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina W.","family":"Cole","sequence":"additional","affiliation":[{"name":"Wingate University School of Pharmacy, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2013,10,15]]},"reference":[{"key":"bibr1-1060028013506562","unstructured":"National Cancer Institute. SEER Stat Fact Sheets: colon and rectum. http:\/\/seer.cancer.gov\/statfacts\/html\/colorect.html. Accessed June 5, 2013."},{"key":"bibr2-1060028013506562","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20138"},{"key":"bibr3-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.04.012"},{"key":"bibr4-1060028013506562","doi-asserted-by":"publisher","DOI":"10.3816\/CCC.2006.n.036"},{"key":"bibr5-1060028013506562","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology: colon cancer. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf. Accessed June 3, 2013."},{"key":"bibr6-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603011"},{"key":"bibr7-1060028013506562","unstructured":"United States Food and Drug Administration. Ziv-aflibercept. http:\/\/www.fda.gov. Accessed May 2, 2013."},{"key":"bibr8-1060028013506562","unstructured":"Zaltrap (ziv-aflibercept) [product information]. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc; 2012."},{"key":"bibr9-1060028013506562","unstructured":"Eyelea (aflibercept) [product information]. Bridgewater, NJ: Regeneron Pharmaceuticals, Inc; 2011."},{"key":"bibr10-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2012.08.001"},{"key":"bibr11-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1038\/nature04483"},{"key":"bibr12-1060028013506562","doi-asserted-by":"publisher","DOI":"10.2165\/11317600-000000000-00000"},{"key":"bibr13-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2012.06.002"},{"key":"bibr14-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.110"},{"key":"bibr15-1060028013506562","first-page":"59","volume":"5","author":"He K","year":"2012","journal-title":"Onco Targets Ther"},{"key":"bibr16-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.8201"},{"key":"bibr17-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-3252"},{"key":"bibr18-1060028013506562","volume-title":"Paper presented at: International Society of Gastrointestinal Oncology, 2012 Gastrointestinal Oncology Conference","author":"Mitchell P"},{"key":"bibr19-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.9237"},{"key":"bibr20-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305"},{"key":"bibr21-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70477-1"},{"key":"bibr22-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt231"},{"key":"bibr23-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"bibr24-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.4_suppl.417"},{"key":"bibr25-1060028013506562","unstructured":"Red book\n                      \u2122\n                      . Micromedex\n                      \u00ae\n                      . Healthcare Series [internet database]. Greenwood Village, CO: Thomson Healthcare."},{"key":"bibr26-1060028013506562","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013506562","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013506562","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013506562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:28Z","timestamp":1777374868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013506562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1177\/1060028013506562"],"URL":"https:\/\/doi.org\/10.1177\/1060028013506562","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,15]]}}}